Accordingly, in the present study, we observed a decrease in metabolic syndrome‐related outcomes, such as body weight gain, adiposity, gene expression of inflammatory markers and leptin availability, in HFD‐CAS + ABX mice relative to HFD‐CAS non‐treated counterparts, at both timepoints. This evidence concerns the gene LEP and metabolic syndrome.